Skip to content

Psychedelic-assisted therapy: all studies

Page 293 of 293: studies 2,921 to 2,926 of 2,926, newest first. Back to the psychedelic-assisted therapy overview

Research

Assessing the Impact of Ketamine-Assisted Multimodal Therapy on Depressive Symptoms: A Longitudinal Pre-Post BDI-II Study with Exploratory Follow-Up Analysis

Anja Frank, Mario H W Scheib preprint

Introduction: Europe faces a worsening mental health crisis, with nearly half of the population (46%) reporting emotional or psychological issues, such as depression, within the last year. One in six Europeans is currently affected by mental health problems, equating to approximately 84 million individuals across the continent (Nawrocka, 2023). Method: This study examines the impact of a...

MDMA-Based Psychotherapy in Treatment-Resistant Post-traumatic Stress Disorder (PTSD): A Brief Overview of Current Evidence

Preprints.org Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al. 1 citation preprint

Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved Pharmacotherapy and Psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we reviewed clinical trials and research on...

The FDA Backdoor to MDMA Rescheduling

SSRN Electronic Journal Vincent Joralemon preprint

MDMA is currently a Schedule I controlled substance, the most restrictive category under the Controlled Substances Act. But Lykos Therapeutics' (formerly MAPS PBC) pending New Drug Application for MDMA-assisted therapy as a treatment for PTSD may force the Drug Enforcement Administration's hand: FDA approval supplies the "accepted medical use" that Schedule I drugs are statutorily denied,...

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: the case for a hybrid group-based delivery model

Christopher P. Albertyn, Jérémie Richard, Ron Joseph Shore et al. preprint

Demoralization syndrome (DS) - a distinct clinical entity characterized by helplessness, hopelessness, and a persistent loss of meaning - affects approximately one in five Canadians with advanced cancer and is associated with increased desire for hastened death, negative clinical outcomes, and higher economic burden, yet recognition and treatment of DS remains suboptimal in modern oncology....

REDUCED PSYCHEDELIC EFFECTS OF KETAMINE INFUSION AFTER ELECTROCONVULSIVE THERAPY: A REPORT ON THREE CASES.

Emmanuel Kiiza Mwesiga, Alinaitwe Racheal, Janet Nakigudde et al. preprint

Psychedelic side effects of ketamine limit its use for the treatment of suicide ideations. Psychedelic effects after ketamine infusion were assessed in two patients received prior electroconvulsive therapy (ECT) and one who had not. Patients who received ECT prior to the infusion had lower mean scores on all domains of the hallucinogen rating scale compared to the patient who did not receive...

Observational cohort study of a group-based VR program to improve mental health and wellbeing in people with life-threatening illnesses

Joe Hardy, Hannes Kettner, David R. Glowacki et al. preprint

Introduction. Being diagnosed with a life-threatening illness (LTI) is often accompanied by feelings of fear, uncertainty, and loneliness that can severely impact mental health. Relatively few interventions are available to address the existential concerns of individuals facing LTI, while treatment of the underlying physical ailment typically remains the priority of the healthcare system....

DOI: 10.31234/osf.io/rs8ny (opens in new tab) Virtual reality Mental health Serious illness Digital therapeutics